Clinical trial Recruiting at 1 site Observational Ages 18 and up

Piperacillin Prophylaxis in Major Liver and Pancreatic Surgery

Official title: PROPHTAZ: Evaluation of Pharmacokinetic/Pharmacodynamic Target Attainment of Piperacillin During Major Hepatic and Pancreatic Surgery, a Prospective Observational Pharmacokinetic Study

Run by Central Hospital, Nancy, France · NCT07558681 · Data updated 2026-11-12

This study tests whether piperacillin/tazobactam given around surgery reliably reaches the right levels to help prevent infections in adults undergoing major liver or pancreatic surgery.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment60 (estimated)
SponsorCentral Hospital, Nancy, France
Academic / other
Locations2 sites (Vandœuvre-lès-Nancy, Lorraine and 1 other locations)
StatusRecruiting
StartedSeptember 25, 2026
Main results expectedJanuary 1, 2027
Study endsMay 1, 2027
Registry record updatedOctober 2, 2026
Trial IDNCT07558681 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 years and older scheduled for major hepatic or pancreatic surgery and receiving piperacillin/tazobactam as perioperative prophylaxis.

Probably not a fit

Patients who do not experience altered PK/PD for piperacillin during surgery or who do not encounter suboptimal exposure may see no direct benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study examines the perioperative pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in adults undergoing major hepatic or pancreatic surgery. It focuses on whether standard dosing achieves target drug exposure despite the physiological changes that occur during these operations. The goal is to understand how factors like fluid shifts and hypoalbuminemia affect antibiotic levels during the perioperative period. Data will help determine if current prophylaxis regimens meet PK/PD targets in high-risk surgical patients. No interventional treatment changes are prescribed within the study protocol.

Why it matters

Potential benefit: If successful, the study could inform more reliable perioperative antibiotic dosing to reduce surgical site infections in high-risk liver and pancreas surgeries.

How similar studies have gone: Previous work in antibiotic PK/PD has shown variability in major surgery; this study builds on that by focusing on piperacillin/tazobactam in hepatic/pancreatic procedures.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults \> or = to 18 years old
* Scheduled for major hepatic or pancreatic surgery
* Receiving piperacillin/tazobactam as perioperative antibiotic prophylaxis according to guidelines

Exclusion Criteria:

* decline to participate
* Known allergy of beta-lactam

Where it's running

  • CHRU de NANCY
    Nancy, France
    Recruiting
  • CHRU de Nancy
    Vandœuvre-lès-Nancy, Lorraine, France
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.